Physician profile
Michael I Levy
NPI 1912124959
$3,623.43
in general payments reported to CMS, 2019-2025
18 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $504 · 2021: $886 · 2022: $754 · 2023: $503 · 2024: $280 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,124 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.97 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,089.11 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $533.83 | 2019-2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $444.04 | 2019-2023 | Invega Sustenna |
| Alkermes, INC. | $349.26 | 2020-2025 | Aristada, Lybalvi |
| Allergan, INC. | $246.01 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $170.66 | 2022-2025 | Rexulti |
| Antares Pharma, INC. | $146.92 | 2020-2021 | |
| Indivior INC. | $115.26 | 2022-2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $93.38 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $87.99 | 2019 | |
| Eisai INC. | $81.51 | 2021 | |
| Novo Nordisk INC | $65.06 | 2020-2024 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2022 | |
| Amgen INC. | $44.23 | 2021-2022 | |
| Almatica Pharma LLC | $41.44 | 2022-2024 | Loreev Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $28.08 | 2022-2025 | Contrave |
| Abbott Laboratories | $24.22 | 2022 | |
| Neurocrine Biosciences, INC. | $15.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.